Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent influenza virus subunit vaccine (Ab&B Bio-tech)
- Development stage
- Phase 4
- Lead developer
- Ab&B Bio-tech Co., Ltd.
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The quadrivalent influenza virus subunit vaccine developed by Jiangsu Ab&B Biotechnology Co., Ltd. is a biologic vaccine designed for the prevention of seasonal influenza. It is a subunit formulation containing purified hemagglutinin antigens from four influenza virus strains: A/H1N1 (California/7/2009), A/H3N2 (Switzerland/9715293/2013), B/Yamagata (Phuket/3073/2013), and B/Victoria (Brisbane/60/2008). Unlike split-virion vaccines, subunit vaccines contain only the surface antigens (hemagglutinin and neuraminidase), which typically results in a higher purity profile and reduced reactogenicity, making it particularly suitable for pediatric populations. The vaccine is administered via intramuscular injection. In China, the version for individuals aged 3 years and older was approved in May 2023, while a pediatric version for children aged 6 to 35 months has completed Phase III clinical trials and is under regulatory review.
- Brand names
- Huierkangxin
- Other names
- Ab&B quadrivalent influenza subunit vaccineJiangsu Ab&B quadrivalent influenza vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on quadrivalent influenza virus subunit vaccine (Ab&B Bio-tech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent influenza virus subunit vaccine (Ab&B Bio-tech).